TNFRSF17 and Miyoshi myopathy: Recent investigations have also shown that BCMA may represent a biomarker for the diagnosis of, monitoring of and therapeutic response to MM treatments, in both MM patients with secretory features (i.e., presence of tumour-related factors in peripheral blood) and in patients with non-secretory MM, in which it is more difficult to track the disease using conventional markers.